Holen Sie sich die Stockscreener-App
13.70
2.93%
0.39
Schlusskurs vom Vortag:
$13.31
Offen:
$13.29
24-Stunden-Volumen:
129.08K
Relative Volume:
0.67
Marktkapitalisierung:
$298.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+4.38%
1M Leistung:
+1.03%
6M Leistung:
-1.58%
1J Leistung:
+0.00%
1-Tages-Spanne:
$13.29
$13.90
1-Wochen-Bereich:
$12.50
$13.90
52-Wochen-Spanne:
$4.88
$19.58
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Firmenname
Aardvark Therapeutics Inc
Sektor
Branche
Telefon
(858) 225-7696
Adresse
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Vergleichen Sie AARD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
13.70 | 289.80M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2025-12-12 | Eingeleitet | William Blair | Outperform |
| 2025-12-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-11-07 | Eingeleitet | BTIG Research | Buy |
| 2025-09-29 | Eingeleitet | Stifel | Buy |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Eingeleitet | BofA Securities | Buy |
| 2025-03-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-03-10 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aardvark Therapeutics Inc Aktie (AARD) Neueste Nachrichten
What AI ML Trends Might Elevate Advance Metering Technology Limiteds Stock ProspectsLong-Term Growth Stocks & Free Unstoppable Trading Performance - earlytimes.in
Aug Gainers: Will Aardvark Therapeutics Inc stock deliver consistent dividends2025 Momentum Check & Community Trade Idea Sharing Platform - moha.gov.vn
Aardvark Therapeutics prices $94M IPO at $16 per share - MSN
Critical Contrast: Aardvark Therapeutics (AARD) and The Competition - Defense World
Aardvark Therapeutics up 9% at $10.10 after Raymond James Strong Buy initiation - MSN
Aardvark Therapeutics (AARD) – Investment Analysts’ Recent Ratings Updates - Defense World
Aardvark Therapeutics initiated with an outperform at Oppenheimer - MSN
Oppenheimer initiates Aardvark Therapeutics stock with Outperform rating By Investing.com - Investing.com South Africa
Oppenheimer initiates Aardvark Therapeutics stock with Outperform rating - Investing.com India
Oppenheimer Initiates Coverage of Aardvark Therapeutics (AARD) with Outperform Recommendation - Nasdaq
Aardvark Therapeutics, Inc.(NasdaqGS: AARD) added to NASDAQ Biotechnology Index - marketscreener.com
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Is Aardvark Therapeutics Inc. stock attractive for hedge fundsTrade Analysis Summary & Risk Adjusted Buy/Sell Alerts - bolumsonucanavari.com
What risks investors should watch in Aardvark Therapeutics Inc. stockMarket Risk Report & AI Forecast for Swing Trade Picks - Улправда
Will Aardvark Therapeutics Inc. stock maintain dividend yieldJuly 2025 Sector Moves & Smart Money Movement Tracker - DonanımHaber
Can Aardvark Therapeutics Inc. stock attract ESG capital inflows2025 Market Trends & Fast Moving Stock Trade Plans - DonanımHaber
How resilient is Aardvark Therapeutics Inc. stock in market downturns2025 Market Sentiment & Technical Pattern Based Signals - Улправда
Insider Buying: Aardvark Therapeutics CEO, Secretary & Director Bought US$101k Of Shares - simplywall.st
HC Wainwright Has Negative Outlook for AARD FY2025 Earnings - Defense World
Aardvark Therapeutics (NASDAQ:AARD) CEO Tien-Li Lee Purchases 7,000 Shares - MarketBeat
Aardvark Therapeutics (NASDAQ:AARD) CFO Purchases $43,200.00 in Stock - MarketBeat
Insider Stock Purchases: December 13, 2025 - Quiver Quantitative
Analysts’ Top Healthcare Picks: Aardvark Therapeutics, Inc. (AARD), Eli Lilly & Co (LLY) - The Globe and Mail
William Blair initiates coverage on Aardvark Therapeutics stock with Outperform rating - Investing.com Canada
Sun Nelson, CFO, buys Aardvark Therapeutics shares worth $43,200 By Investing.com - Investing.com Nigeria
Insider Buying: Nelson Sun Acquires Additional Shares of Aardvar - GuruFocus
Lee Tien-Li, CEO of Aardvark, buys $101k in AARD stock - Investing.com Australia
Sun Nelson, CFO, buys Aardvark Therapeutics shares worth $43,200 - Investing.com
Aardvark Therapeutics Executives Increase Their Holdings - TradingView — Track All Markets
CFO Sun Buys 3,000 ($43.2K) Of Aardvark Therapeutics Inc [AARD] - TradingView — Track All Markets
William Blair Initiates Coverage of Aardvark Therapeutics (AARD) with Outperform Recommendation - Nasdaq
Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst - Sahm
William Blair Initiates Aardvark Therapeutics With Outperform Rating - marketscreener.com
Aardvark Therapeutics: Innovative Therapies for PWS and Obesity with Significant Market Potential - TipRanks
Aardvark Therapeutics stock rises 13% on positive trial updates, BTIG maintains Buy By Investing.com - Investing.com South Africa
Aardvark Therapeutics’ Promising Progress and Market Potential: Analyst Recommends Buy - TipRanks
Aardvark Therapeutics stock rises 13% on positive trial updates, BTIG maintains Buy - Investing.com Canada
Raymond James reiterates Strong Buy on Aardvark Therapeutics stock with $47 target - Investing.com Nigeria
Raymond James reiterates Strong Buy on Aardvark Therapeutics stock with $47 target By Investing.com - Investing.com South Africa
Aardvark doses first Australian patient in phase 3 PWS hunger trial - Investing.com Nigeria
Finanzdaten der Aardvark Therapeutics Inc-Aktie (AARD)
Es liegen keine Finanzdaten für Aardvark Therapeutics Inc (AARD) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
28.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):